Scaffold Thrombosis after Percutaneous Coronary Intervention with ABSORB Bioresorbable Vascular Scaffold A Systematic Review and Meta-Analysis

JACC: Cardiovascular Interventions

Volumn 9, Issue 1, 2016, Pages 12-24

  Lipinski, Michael J ^a   Escarcega, Ricardo O ^a   Baker, Nevin C ^a   Benn, Hadiya A ^a   Gaglia, Michael A ^a   Torguson, Rebecca ^a   Waksman, Ron ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

bioresorbable vascular scaffold; meta analysis; outcomes; scaffold thrombosis

Indexed keywords

ACUTE CORONARY SYNDROME; BIORESORBABLE SCAFFOLD; BIORESORBABLE VASCULAR SCAFFOLD; COCHRANE LIBRARY; COMPARATIVE STUDY; DRUG ELUTING STENT; FOLLOW UP; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; MEDLINE; META ANALYSIS; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVIEW; SCAFFOLD THROMBOSIS; STABLE ANGINA PECTORIS; SYSTEMATIC REVIEW; TASK PERFORMANCE; THROMBOSIS; ADVERSE EFFECTS; AGED; ANGINA, STABLE; BIODEGRADABLE IMPLANT; CHI SQUARE DISTRIBUTION; CORONARY ARTERY DISEASE; CORONARY THROMBOSIS; DEVICES; FEMALE; MALE; MIDDLE AGED; MORTALITY; MYOCARDIAL INFARCTION; ODDS RATIO; PROSTHESIS DESIGN; RISK ASSESSMENT; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME;

ABSORBABLE IMPLANTS; ACUTE CORONARY SYNDROME; AGED; ANGINA, STABLE; CHI-SQUARE DISTRIBUTION; CORONARY ARTERY DISEASE; CORONARY THROMBOSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; ODDS RATIO; PERCUTANEOUS CORONARY INTERVENTION; PROSTHESIS DESIGN; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84952941193     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2015.09.024     Document Type: Article

References (50)

1. S. Brugaletta, J.H. Heo, H.M. Garcia-Garcia, and et al. Endothelial-dependent vasomotion in a coronary segment treated by ABSORB everolimus-eluting bioresorbable vascular scaffold system is related to plaque composition at the time of bioresorption of the polymer: indirect finding of vascular reparative therapy? Eur Heart J 33 2012 1325 1333
2. M.J. Lipinski, R.O. Escarcega, T. Lhermusier, and R. Waksman The effects of novel, bioresorbable scaffolds on coronary vascular pathophysiology J Cardiovasc Transl Res 7 2014 413 425
3. Y. Onuma, P.W. Serruys, L.E. Perkins, and et al. Intracoronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the human optical coherence tomography images in the ABSORB trial Circulation 122 2010 2288 2300
4. P.W. Serruys, Y. Onuma, D. Dudek, and et al. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes J Am Coll Cardiol 58 2011 1578 1588
5. J.A. Ormiston, P.W. Serruys, E. Regar, and et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial Lancet 371 2008 899 907
6. J.A. Ormiston, P.W. Serruys, Y. Onuma, and et al. First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study Circ Cardiovasc Interv 5 2012 620 632
7. D. Capodanno, T. Gori, H. Nef, and et al. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry EuroIntervention 10 2015 1144 1153
8. R.P. Kraak, M.E. Hassell, M.J. Grundeken, and et al. Initial experience and clinical evaluation of the Absorb bioresorbable vascular scaffold (BVS) in real-world practice: the AMC Single Centre Real World PCI Registry EuroIntervention 10 2015 1160 1168
9. M.J. Lipinski, T. Lhermusier, R.O. Escarcega, and et al. Bivalirudin versus heparin for percutaneous coronary intervention: an updated meta-analysis of randomized controlled trials Cardiovasc Revasc Med 15 2014 315 322
10. D. Capodanno, M. Joner, and M. Zimarino What about the risk of thrombosis with bioresorbable scaffolds? EuroIntervention 11 Suppl V 2015 V181 V184
11. Y. Ishibashi, S. Nakatani, and Y. Onuma Definite and probable bioresorbable scaffold thrombosis in stable and ACS patients EuroIntervention 11 2015 e1 e2
12. D. Moher, A. Liberati, J. Tetzlaff, and D.G. Altman Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement Ann Intern Med 151 2009 264 269 W64
13. D.E. Cutlip, S. Windecker, R. Mehran, and et al. Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351
14. J.L. Peters, A.J. Sutton, D.R. Jones, K.R. Abrams, and L. Rushton Comparison of two methods to detect publication bias in meta-analysis JAMA 295 2006 676 680
15. J.M. Bland, and S.M. Kerry Statistics notes. Weighted comparison of means BMJ 316 1998 129
16. P.W. Serruys, Y. Onuma, J.A. Ormiston, and et al. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes Circulation 122 2010 2301 2312
17. A. Abizaid, J. Ribamar Costa Jr., A.L. Bartorelli, and et al. The ABSORB EXTEND study: preliminary report of the twelve-month clinical outcomes in the first 512 patients enrolled EuroIntervention 10 2015 1396 1401
18. A. Ielasi, B. Cortese, A. Varricchio, and et al. Immediate and midterm outcomes following primary PCI with bioresorbable vascular scaffold implantation in patients with ST-segment myocardial infarction: insights from the multicentre "Registro ABSORB Italiano" (RAI registry) EuroIntervention 11 2015 157 162
19. T. Muramatsu, Y. Onuma, R.J. van Geuns, and et al. 1-year clinical outcomes of diabetic patients treated with everolimus-eluting bioresorbable vascular scaffolds: a pooled analysis of the ABSORB and the SPIRIT trials J Am Coll Cardiol Intv 7 2014 482 493
20. J. Kochman, M. Tomaniak, A. Pietrasik, and et al. Bioresorbable everolimus-eluting vascular scaffold in patients with ST-segment elevation myocardial infarction: Optical coherence tomography evaluation and clinical outcomes Cardiol J 2014 Nov 27 [E-pub ahead of print]
21. L. Rzeszutko, Z. Siudak, A. Wlodarczak, and et al. Use of bioresorbable vascular scaffolds in patients with stable angina and acute coronary syndromes. Polish National Registry Kardiol Pol 72 2014 1394 1399
22. L. Azzalini, and P.L. L'Allier Bioresorbable vascular scaffold thrombosis in an all-comer patient population: single-center experience J Invasive Cardiol 27 2015 85 92
23. P.W. Serruys, B. Chevalier, D. Dudek, and et al. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial Lancet 385 2015 43 54
24. Abizaid A. ABSORB EXTEND: one year results in moderately complex lesions (abstr.). Presented at: EuroPCR. Paris, France, 2015.
25. Eeckhout E. ABSORB FIRST real-world registry: one-year clinical outcomes on 958 patients (abstr.). Presented at: EuroPCR. Paris, France, 2015.
26. J. Wohrle, C. Naber, T. Schmitz, and et al. Beyond the early stages: insights from the ASSURE registry on bioresorbable vascular scaffolds EuroIntervention 11 2015 149 156
27. S. Brugaletta, T. Gori, A.F. Low, and et al. Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction) J Am Coll Cardiol Intv 8 2015 189 197
28. van Geuns RJ. BVS EXPAND: 6-month results (abstr.). Presented at: EuroPCR. Paris, France, 2014.
29. B. Cortese, A. Ielasi, E. Romagnoli, and et al. Clinical comparison with short-term follow-up of bioresorbable vascular scaffold versus everolimus-eluting stent in primary percutaneous coronary interventions Am J Cardiol 116 2015 705 710
30. R. Diletti, A. Karanasos, T. Muramatsu, and et al. Everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with ST-segment elevation myocardial infarction: BVS STEMI first study Eur Heart J 35 2014 777 786
31. B. Vaquerizo, A. Barros, S. Pujadas, and et al. Bioresorbable everolimus-eluting vascular scaffold for the treatment of chronic total occlusions: CTO-ABSORB pilot study EuroIntervention 11 2015 555 563
32. S. Puricel, D. Arroyo, N. Corpataux, and et al. Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds J Am Coll Cardiol 65 2015 791 801
33. Hamm C. 30-days-follow-up of the German-Austrian-ABSORB register: GABI-R (abstr.). Presented at: EuroPCR. Paris, France, 2015.
34. D. Dudek, L. Rzeszutko, W. Zasada, and et al. Bioresorbable vascular scaffolds in patients with acute coronary syndromes: the POLAR ACS study Pol Arch Med Wewn 124 2014 669 677
35. V. Kocka, M. Maly, P. Tousek, and et al. Bioresorbable vascular scaffolds in acute ST-segment elevation myocardial infarction: a prospective multicentre study 'Prague 19' Eur Heart J 35 2014 787 794
36. Hernandez FH. REPARA: acute performance from Iberian real-world experience (abstr.). Presented at: EuroPCR. Paris, France, 2015.
37. D. Robaei, L.M. Back, S.Y. Ooi, M.R. Pitney, and N. Jepson Everolimus-eluting bioresorbable vascular scaffold implantation in real world and complex coronary disease: procedural and 30-day outcomes at two Australian centres Heart Lung Circ 24 2015 854 859
38. C. Costopoulos, A. Latib, T. Naganuma, and et al. Comparison of early clinical outcomes between ABSORB bioresorbable vascular scaffold and everolimus-eluting stent implantation in a real-world population Catheter Cardiovasc Interv 85 2015 E10 E15
39. T. Gori, E. Schulz, U. Hink, and et al. Clinical, angiographic, functional, and imaging outcomes 12 months after implantation of drug-eluting bioresorbable vascular scaffolds in acute coronary syndromes J Am Coll Cardiol Intv 8 2015 770 777
40. T. Gori, E. Schulz, U. Hink, and et al. Early outcome after implantation of Absorb bioresorbable drug-eluting scaffolds in patients with acute coronary syndromes EuroIntervention 9 2014 1036 1041
41. M. Jaguszewski, J.R. Ghadri, M. Zipponi, and et al. Feasibility of second-generation bioresorbable vascular scaffold implantation in complex anatomical and clinical scenarios Clin Res Cardiol 104 2014 124 135
42. T. Kajiya, M. Liang, R.K. Sharma, and et al. Everolimus-eluting bioresorbable vascular scaffold (BVS) implantation in patients with ST-segment elevation myocardial infarction (STEMI) EuroIntervention 9 2013 501 504
43. A. Mattesini, G.G. Secco, G. Dall'Ara, and et al. ABSORB biodegradable stents versus second-generation metal stents: a comparison study of 100 complex lesions treated under OCT guidance J Am Coll Cardiol Intv 7 2014 741 750
44. S. Ojeda, M. Pan, M. Romero, and et al. Outcomes and computed tomography scan follow-up of bioresorbable vascular scaffold for the percutaneous treatment of chronic total coronary artery occlusion Am J Cardiol 115 2015 1487 1493
45. J. Wiebe, H. Mollmann, A. Most, and et al. Short-term outcome of patients with ST-segment elevation myocardial infarction (STEMI) treated with an everolimus-eluting bioresorbable vascular scaffold Clin Res Cardiol 103 2014 141 148
46. H. Kawamoto, V.F. Panoulas, K. Sato, and et al. Impact of strut width in periprocedural myocardial infarction: a propensity-matched comparison between bioresorbable scaffolds and the first-generation sirolimus-eluting stent J Am Coll Cardiol Intv 8 2015 900 909
47. A. Karanasos, N. Van Mieghem, N. van Ditzhuijzen, and et al. Angiographic and optical coherence tomography insights into bioresorbable scaffold thrombosis: single-center experience Circ Cardiovasc Interv 8 5 2015 May
48. L. Timmers, P.R. Stella, and P. Agostoni Very late bioresorbable vascular scaffold thrombosis following discontinuation of antiplatelet therapy Eur Heart J 36 2014 393
49. A. Karanasos, R.J. van Geuns, F. Zijlstra, and E. Regar Very late bioresorbable scaffold thrombosis after discontinuation of dual antiplatelet therapy Eur Heart J 35 2014 1781
50. B. Cortese, D. Piraino, A. Ielasi, G. Steffenino, and P.S. Orrego Very late bioresorbable vascular scaffold thrombosis due to late device recoil Int J Cardiol 189 2015 132 133